MCK

Strategic Conclusion

• Recommendation: Buy
• Why? The stock trades above both its 50-day and 200-day moving averages, confirming a medium-term uptrend, while the technical score is 80/100. Analyst consensus is strongly positive (1.88 mean, 19 buy ratings), and the P/E of 22.21 is reasonable for a healthcare distributor with stable cash flows. The main risk is short-term momentum: MACD is below its signal line and RSI is neutral, so buying on dips is preferable to chasing.
• Ideal profile: Long-term investor with a 12-month horizon; short-term traders should wait for a MACD crossover or a breakout above $900.
• Price range: Accumulation zone $850–$875; first target $950, second target $999 (52-week high); stop-loss at $830 (below SMA200).
• Practical action: Buy on pullbacks toward the SMA50 near $866 or at current levels. Add on a daily close above $900. If already holding, maintain the position and keep the stop-loss at $830.

1. Recent Price & Momentum

• Current price $874.65 is 12.4% below the 52-week high of $999.00 and 27.2% above the 52-week low of $687.68 — closer to the upper half of the range, but not at the top.
• The stock is in a sideways-to-bullish consolidation phase: it remains above both key moving averages, but the recent pullback from the high has stalled momentum.
• Short-term scenario: a bounce toward $900 is likely if buying pressure returns; failure to hold above $850 could lead to a retest of the SMA200 at $844.

2. Valuation (P/E)

• P/E TTM is 22.21, which is moderate for a large-cap healthcare company with defensive earnings and consistent growth.
• The multiple is not stretched, and the current price does not appear to fully discount aggressive future growth — it leaves room for upside if earnings continue to trend positively.
• The low dividend yield (0.54%) indicates investors are paying for growth and stability rather than income.

3. Technical Analysis

• SMA50 ($866.67) is above SMA200 ($844.15) — a golden-cross configuration that supports the medium-term uptrend.
• RSI(14) at 44.3 is neutral, meaning there is no overbought or oversold pressure; the stock has room to move in either direction.
• MACD (5.88) is below its signal line (10.44) with a negative histogram (-4.56), signaling bearish short-term momentum.
• Technical score: 80/100 → BUY, driven mainly by the moving-average structure and analyst support, but tempered by weak MACD momentum.

4. Analyst Consensus

• Mean rating 1.88/5 with 19 buy, 5 hold, and 0 sell — a clear bullish tilt.
• This aligns with the technical score’s buy signal, but the MACD weakness suggests analysts are looking at a longer-term story rather than an immediate breakout.
• The consensus supports accumulating on weakness rather than chasing strength.